There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 1 | 2 | 1475 |
| 1 | 1 | 1474.6 |
| 2 | 7 | 1474.5 |
| 2 | 7 | 1474.4 |
| 2 | 2 | 1474.3 |
| Ask | Qty | Orders |
|---|---|---|
| 1475.8 | 3 | 18 |
| 1475.9 | 1 | 7 |
| 1476 | 1 | 16 |
| 1476.1 | 2 | 24 |
| 1476.2 | 4 | 16 |
Our researchers has found no immediate positive insights for this stock. We'll update this space as soon as we find something.
Rubicon Research was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name ‘Rubicon Consultants Private Limited’, pursuant to a certificate of incorporation issued by the RoC.Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by FS, and the company), it is the only Indian pharmaceutical player with a complete focus on regulated markets.The company’s multi-disciplinary, data-driven, and return on investment (ROI) centric product selection framework is geared towards identifying sustainable opportunities for new product development. It identifies and pursues such opportunities in a manner that provides it a competitive advantage by leveraging its development, manufacturing, and commercialization capabilities to create and grow its share of the market.Business area of the companyRubicon Research, incorporated in 1999, is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products.
Further, the company has robust sales and distribution capabilities in the US.Products of the companyMetoprolol TartrateCyclobenzaprine Hydrochloride Carbidopa-LevodopaDiclofenac PotassiumBaclofenRabeprazole SodiumLidocaine HydrochlorideTramadol HydrochlorideHistory and milestones2007: Received investment from Kotak India Venture Fund - I, Kotak India Venture Limited and Kotak Employees Investment Trust.2011: Commencement of manufacturing of certain special drugs in Ambernath Manufacturing Facility.2011: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility for tablet manufacturing and secondary packaging by Medicines and Healthcare Products Regulatory Agency, United Kingdom.2013: Receipt of GMP clearance approval for Ambernath Manufacturing Facility from Department of Health and Ageing Therapeutic Goods Administration, Australian Government.2014: Receipt of approval for its product i.e., ‘metoprolol tartrate tablets’ from the Food Drug Administration, United State of America.2016: Acquisition of majority stake by ECP III Pte Ltd.2017: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility from the Ministerio De Sandidad, Servicios Sociales E Igualdad, Spain.2019: Acquisition of majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd.2019: Acquisition of Impopharma Canada Limited by Rubicon Research Canada Limited2021: Acquired the business of Meditab Specialities Limited on a slump sale basis.2022: Set up own sales and marketing front end in US via its Material Subsidiary.2023: Receipt of certificate of GMP compliance for Satara Manufacturing Facility of non-sterile liquid drug manufacturer and pre-approval coverage provided for non-sterile liquid product by US FDA.2024: Acquisition of Validus Pharmaceuticals LLC.2024: ANDA pre-approval drug inspection of nasal spray block at Ambernath Manufacturing Facility by USFDA.2024: Receipt of supplement approval for Thane RD Facility as a testing site of drug substance - lead test from USFDA.2024: Received USFDA establishment inspection report for Ambernath Manufacturing Facility.2024: Commencement of manufacturing of nasal products at Ambernath Manufacturing Facility.2025: Received new drug application approval from USFDA for Lopressor (Metoprolol Tartrate) oral solution.2025: Received USFDA establishment inspection report for Thane RD Facility.2025: Acquisition of Pithampur Manufacturing Facility from Alkem Laboratories Limited.2025: Acquisition of AIM RX 3PL LLC.
Over the last 6 months, Rubicon Research Ltd has given a return of 132.29%. The stock was priced at ₹654.45 on 27 Jan 2026 and has Rise to ₹1,520.20 as of 25 Jul 2026, a change of ₹865.75 per share.
The intraday low for Rubicon Research Ltd on the NSE today was ₹1,476.10. The stock's 52-week low stands at ₹570.75, recorded on 24 Oct 2025. Today's low is 158.62% above the 52-week low, indicating the stock is trading well above its yearly lows.
The all-time high (ATH) for Rubicon Research Ltd was ₹1,525.40, recorded on 23 Jul 2026. At the current price of ₹1,520.20, the stock is trading 0.34% below its all-time high. The all-time low recorded was ₹577.25 on 24 Oct 2025.
For Q4 FY26, Rubicon Research Ltd reported: Revenue (Net Sales): ₹3898.78 Cr - Up 29.22% year-on-year from ₹3017.11 Cr in Q3 FY26. Net Income (PAT): ₹700.20 Cr - Up 88.32% year-on-year from ₹371.81 Cr in Q3 FY26.
No,Rubicon Research Ltd has not declared any dividend over the past 5 years. The company paid a total dividend of 1.50 per share between FY2022 and FY2026, with the most recent dividend of ₹1.50 per share for May 26, with an ex-dividend date of 07 Aug 2026. At the current market price of ₹1,520.20, the trailing dividend yield of Rubicon Research Ltd stands at N/A%.
As of 25 Jul 2026, the share price of Rubicon Research Ltd is ₹1,520.20 on the NSE and ₹1,522.00 on the BSE. The stock opened at ₹1,529.70, touched a high of ₹1,560.00 and a low of ₹1,476.10 during today's session.
Rubicon Research Ltd has delivered 141.99% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹1,560.00 on 24 Jul 2026 and a 52-week low of ₹570.75 on 24 Oct 2025. It is currently trading at ₹1,520.20 as of 25 Jul 2026.
Rubicon Research Ltd has delivered a N/A% absolute return over the past 5 years, equivalent to a CAGR of N/A% per annum. The stock was priced at ₹N/A in Jul 2021 and has fallen to ₹1,520.20 as of 25 Jul 2026. An investment of ₹1,00,000 in Rubicon Research Ltd five years ago would be worth ₹N/A today.
Rubicon Research Ltd has delivered a return of 58.56% over the last 3 months. The stock was trading at ₹938.70 on 24 Apr 2026 and is currently at ₹1,520.20 as of 25 Jul 2026, reflecting a Gain of ₹581.50 per share over this period.
The intraday high for Rubicon Research Ltd on the NSE today (25 Jul 2026) was ₹1,560.00. This compares to the 52-week high of ₹1,560.00 recorded on 24 Jul 2026. Today's high was 0.00% above the 52-week high.
